Dai Yuran, Jin Yudi, Lan Ailin, Ding Nan, Jiang Linshan, Liu Shengchun
Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Pathology, Chongqing University Cancer Hospital, Chongqing, China.
Front Oncol. 2022 Apr 4;12:873354. doi: 10.3389/fonc.2022.873354. eCollection 2022.
Metastatic rectal cancer (mRC) of the breast is an extremely rare clinical situation. There are few reported cases in domestic or foreign literature. The clinicopathologic characteristics along with the diagnostic and therapeutic strategies of such cases remain relatively unclear. Here, we would like to provide our comprehensive insights into this rare entity.
We present a case that till now is the first reported breast metastasis from rectal cancer pathologically diagnosed as a signet-ring cell carcinoma, and we review the current literature on this rare event. The detailed clinical data, histopathology, management, and follow-up aspects were gathered for analysis.
A total of 15 cases were collected including the current case. Breast metastases from rectal cancer present at an average age of 47.7 years (range, 28 to 69 years) and appear with an average interval of 28.4 months (range, 5 months to 18 years) following primary tumor diagnoses. Of the 15 cases, 8 and 5 are pathologically diagnosed as adenocarcinomas and mucinous adenocarcinomas, respectively. Most cases (11/15) are accompanied by extramammary metastases. About half of the breast metastases (7/15) were to the left. In all cases, the main complaints were palpable mass. The average maximum diameter of the metastatic mass is 2.7 cm (range, 1-11 cm). The majority (8/12) of cases with accessible therapy information exclude the option of local surgery.
Previous cancer history and accurate immunohistochemistry data play critical roles to distinguish mammary metastasis from a primary neoplasm of the breast. Mastectomy and molecular-targeted drugs should be considered with priority if systemic condition supports them.
乳腺转移性直肠癌(mRC)是一种极其罕见的临床情况。国内外文献报道的病例很少。此类病例的临床病理特征以及诊断和治疗策略仍相对不清楚。在此,我们希望提供对此罕见实体的全面见解。
我们报告一例目前经病理诊断为印戒细胞癌的直肠癌乳腺转移病例,这是首例报道,并回顾了关于这一罕见事件的现有文献。收集详细的临床数据、组织病理学、治疗及随访情况进行分析。
包括本病例在内共收集到15例。直肠癌乳腺转移患者的平均年龄为47.7岁(范围28至69岁),出现转移的平均间隔时间为原发肿瘤诊断后28.4个月(范围5个月至18年)。15例中,8例和5例分别经病理诊断为腺癌和黏液腺癌。大多数病例(11/15)伴有乳腺外转移。约一半的乳腺转移(7/15)发生在左侧。所有病例的主要症状均为可触及肿块。转移灶的平均最大直径为2.7 cm(范围1至11 cm)。大多数(8/12)有可用治疗信息的病例不选择局部手术。
既往癌症病史和准确的免疫组化数据对于区分乳腺转移瘤与乳腺原发性肿瘤起着关键作用。如果全身状况允许,应优先考虑乳房切除术和分子靶向药物治疗。